{"schema_version":"secwatch.filing_event.v1","accession":"0000879407-25-000019","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.441847+00:00","generated_at":"2026-05-16T19:01:13.296992+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO for Familial Chylomicronemia Syndrome","bullets":["REDEMPLO (plozasiran) approved by FDA as adjunct to diet to reduce triglycerides in adults with FCS.","Phase 3 PALISADE study showed 80% median triglyceride reduction vs 17% placebo and lower acute pancreatitis incidence.","REDEMPLO is first FDA-approved siRNA medicine for FCS, self-administered quarterly at home.","Approximately 6,500 people in the U.S. live with genetic or clinical FCS.","Arrowhead's first FDA-approved medicine marks transition to a commercial-stage company."],"urls":{"canonical":"https://secwatch.observer/filing/0000879407-25-000019","json":"https://secwatch.observer/filing/0000879407-25-000019.json","markdown":"https://secwatch.observer/filing/0000879407-25-000019.md","text":"https://secwatch.observer/filing/0000879407-25-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000087940725000019/0000879407-25-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000087940725000019/arwr-20251118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T19:01:13.296992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}